[Clinical and laboratory effect of leukinferon in purulent infections].
Clinical trials of human leukocytic alpha-interferon for injections, leukinferon were performed in 51 patients with different forms of surgical purulent infections. It was shown that leukinferon lowered the terms of normalization of body's temperature, leukocytosis, respiratory neutrophilic outbreak and levels of active T-lymphocytes. The same was observed when leukinferon was used prophylactically in cardiosurgical patients. The effect of leukinferon depended on the level of radical operations on primary purulent foci and severity of the patient's state. Leukinferon had immunomodulatory properties and mainly influenced the system of neutrophilic phagocytes. The action was lymphocyte-mediated. The rapid effect of leukinferon makes it necessary to recommend it for treatment of patients with purulent infections as an agent of urgent immunomodulation.
Belotskiĭ
S M
SM
A. V. Vishnevsky Institute of Surgery, Moscow.
Karlov
V A
VA
Filiukova
O B
OB
Kuznetsov
V P
VP
Zueva
V S
VS
Gutsu
E V
EV
Krastin
O A
OA
Snastina
T I
TI
Karpinskaia
T G
TG
D000276:Adjuvants, Immunologic; D001424:Bacterial Infections / Q000188:drug therapy* / Q000276:immunology; D016207:Cytokines / Q000627:therapeutic use*; D004338:Drug Combinations; D005334:Fever / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D007958:Leukocyte Count / Q000187:drug effects; D007964:Leukocytosis / Q000188:drug therapy / Q000209:etiology; D009504:Neutrophils / Q000187:drug effects; D010101:Oxygen Consumption / Q000187:drug effects; D010587:Phagocytosis / Q000187:drug effects; D013492:Suppuration; D013530:Surgical Wound Infection / Q000517:prevention & control; D013601:T-Lymphocytes / Q000187:drug effects
D000276:Adjuvants, Immunologic; D016207:Cytokines; D004338:Drug Combinations; D007370:Interferon Type I; C062252:leukinferon
Kliniko-laboratornyĭ éffekt leĭkinferona pri gnoĭnoĭ infektsii.